Cybin completes its 51st pre-clinical molecule study, with four of these molecules already being advanced to toward clinical evaluations.

The first of five Western Illinois University students with a minor in Cannabis & Culture was part of the school’s spring 2021 graduating class.

Recreational marijuana makes the most headlines, but a large number of cannabis consumers buy and use the plant for medical and wellness reasons.

The much-anticipated IPO for atai Life Sciences (US:ATAI) ended up being anti-climactic instead.

Edward Forchion, the cannabis advocate known as “NJ Weedman,” is running a write-in campaign for New Jersey governor following a successful challenge of his nominating petitions by the Democratic State Committee, NJ.com reports.

Tonya Papanikolov could talk about mushrooms for hours.

Mydecine Innovations Group is a psychedelics company that The Dales Report has been watching closely this past year.

Field Trip completes another preliminary step toward its Phase I clinical trial of FT-104.

Novamind has just completed a strategic investment of US$1 million in a private psychedelics company, as part of a $25 million Series A financing.

MINDCURE announces two, new ketamine-based treatment protocols: one for pain and one for depression. These new protocols will be distributed via iSTRYM.